ERAS Projected Dividend Yield
Erasca Inc ( NASDAQ : ERAS )Erasca, Inc. is a clinical-stage precision oncology company. Co. is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Co. has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. 21 YEAR PERFORMANCE RESULTS |
ERAS Dividend History Detail ERAS Dividend News ERAS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |